These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 32889976)

  • 1. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
    Xie W; Xiao S; Huang H; Zhang Z
    Front Immunol; 2022; 13():847160. PubMed ID: 35300336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Dai C; Wang YN; Tian WN; Huang YH; Jiang M
    Int Immunopharmacol; 2022 Nov; 112():109269. PubMed ID: 36182873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.
    Andrade P; Lopes S; Gaspar R; Nunes A; Magina S; Macedo G
    Dig Dis Sci; 2018 Mar; 63(3):746-754. PubMed ID: 29349693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.
    Zelinkova Z; Bultman E; Vogelaar L; Bouziane C; Kuipers EJ; van der Woude CJ
    World J Gastroenterol; 2012 Dec; 18(47):6967-73. PubMed ID: 23322995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
    Sridhar S; Maltz RM; Boyle B; Kim SC
    Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
    Peer FC; Miller A; Pavli P; Subramaniam K
    Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm.
    Au M; Heddle G; Young E; Ryan E; Graf S; Tee D; Philpott H
    Intern Med J; 2023 Oct; 53(10):1854-1865. PubMed ID: 35760771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis.
    Yang M; Liu W; Deng Q; Liang Z; Wang Q
    Medicine (Baltimore); 2021 Oct; 100(42):e27510. PubMed ID: 34678884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study.
    Cottron C; Treton X; Altwegg R; Reenaers C; Amiot A; Fumery M; Vuitton L; Peyrin-Biroulet L; Bouguen G; Dewit O; Nancey S; Caillo L; Roblin X; Beylot-Barry M; Rivière P; Laharie D
    J Crohns Colitis; 2022 Aug; 16(8):1202-1210. PubMed ID: 35218189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY; Lee Y; Choe BH; Kang B
    Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
    George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
    Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.